ClearStream Technologies Group plc: Registry And Board Appointment
Enniscorthy, Ireland - ClearStream Technologies Group plc (‘ClearStream'), the Irish based specialist developer and manufacturer of medical devices used in the rapidly growing interventional medical market, recently announced the commencement of a European Registry of its ReeKross catheter and also the appointment to the Board of Jean De Schepper as a non-executive director.
The objective of the Registry, which will be carried out at three centres in Holland and at two Ireland, is to provide real case data to support specific claims concerning the superior performance of the ReeKross catheter in the treatment of critical limb ischemia (CLI). This condition is caused by a shortage of blood to the legs as a result of narrowed or blocked arteries. Initial data, collected prior to the registry, has been very encouraging and the first patient data gathered within the registry is consistent with this. Up to 100 patients will be treated in the Registry.
Commenting on this development Andrew Jones, CEO of ClearStream commented: "The success that we are having with the ReeKross will significantly raise the profile and standing of ClearStream in our chosen markets. It also gives us a high margin, well differentiated product that is a market leader. We anticipate it giving us further opportunity to cross sell our other main stream interventional products".
The appointment of Jean De Schepper is an important step in the Company's progression towards its objective of becoming a leading, second tier, medical device company. Mr. de Schepper has had a long and distinguished career in sales, marketing and manufacturing within the European interventional cardiology market. Following his early career with Baxter, he joined Johnson & Johnson. Through different assignments in sales and marketing, in a number of European countries, he rose to become European Managing Director for Johnson & Johnson Interventional Systems, where he initiated the Bene stent trial. This was the landmark multi-center randomized trial for coronary stents, which led to the explosion of stent use in coronary interventional procedures. He has also served as CEO at Conforma, where he had full responsibility for manufacturing and marketing of pharmaceutical base materials and related products. After that, he joined Cordis, a Johnson & Johnson company. During this period he negotiated the reimbursement of the first drug eluting stent, the Cypher, in France. He retains good contacts with key opinion leaders in the European interventional market.
Aged 52, Jean Willy Marguerite Marie Bernard De Schepper's only current directorship is of Medical Devices & Innovations Bvba. In the last five years, he was a director of Johnson & Johnson Medical BV and Johnson & Johnson Medical NV. There are no further matters to disclose regarding Jean De Schepper in accordance with Schedule 2 of the AIM Rules.
Commenting on the appointment, Mike Love, Chairman of ClearStream said: "Jean brings to ClearStream extensive knowledge and experience of the cardio vascular market together with proven skills in managing corporate evolution and growth. The Board is delighted that a man of his reputation and expertise has chosen to join ClearStream. I am sure he will be a great asset to the Group as we look forward to a period of significant expansion."
Jean De Schepper added: "I am extremely pleased to be joining the ClearStream Board at this exciting time in the Company's development. It has a range of market-leading products within its existing portfolio and in the pipeline. I look forward to bringing my industry experience to bear in helping to maximise ClearStream's market penetration."
SOURCE: ClearStream Technologies Group